Compounded vs. Brand-Name GLP-1 Through Telehealth: The Full Comparison

Compounded or brand-name? It's the first major decision you'll face when starting GLP-1 treatment through telehealth — and it involves tradeoffs on price, regulatory status, and medication quality. Neither choice is inherently better; the right one depends on your priorities, budget, and comfort level.

What "Compounded" Actually Means

Compounded semaglutide and tirzepatide are made-to-order by licensed pharmacies using bulk pharmaceutical-grade active ingredients. They are not manufactured by Novo Nordisk or Eli Lilly. They are not FDA-approved. They have not undergone the same large-scale clinical trials as Wegovy, Ozempic, Zepbound, or Mounjaro.

That doesn't mean they're automatically unsafe — compounding pharmacies have been making customized medications for decades, and the process is legal and regulated under both federal (FDCA sections 503A and 503B) and state pharmacy law. But it does mean the quality and consistency depend on the specific pharmacy producing them.

Brand-Name: What You Get

FDA-approved GLP-1 medications — Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo — come with the full weight of FDA oversight. That means each batch is tested for potency, purity, and consistency. Extensive clinical trial data supports their safety and efficacy. Manufacturing follows current Good Manufacturing Practice (cGMP) regulations. And if a problem occurs, there's a clear pathway for adverse event reporting and product recall.

The tradeoff: they cost significantly more. Wegovy's list price is $1,349/month. Zepbound runs about $1,000/month. Even with manufacturer savings cards that bring costs down to $149–349/month, brand-name is typically more expensive than compounded alternatives.

Compounded: What You Get

Compounded GLP-1 medications cost $130–350/month depending on medication, dose, and pharmacy. They're available without insurance or prior authorization. They may offer dosing flexibility that brand-name products don't (custom doses, different concentrations). But quality varies by pharmacy, the regulatory environment is changing rapidly, and the FDA has raised concerns about potency variation and dosing errors.

The Regulatory Shift in 2026

The compounded GLP-1 landscape is changing fast. The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would restrict large-scale compounding by outsourcing facilities. If finalized (public comment period closes June 29, 2026), this could reduce the supply and potentially increase prices for compounded products. 503A patient-specific compounding is less directly affected but may face increased scrutiny.

Making the Choice

Choose brand-name if: You have insurance coverage or can access manufacturer savings programs. You want the assurance of FDA-approved products with proven bioequivalence. You're uncomfortable with the quality variability associated with compounding. You prefer products with extensive published safety data.

Choose compounded if: You're paying cash and need affordable access ($130–300/month vs. $800+/month). Your provider has vetted the compounding pharmacy and is confident in the quality. You understand and accept that compounded medications are not FDA-approved. You want dosing flexibility not available in fixed-dose brand-name products.